Tigecycline's GI Side Effects in Clinical Trials
Tigecycline, an IV glycylcycline antibiotic, frequently causes gastrointestinal issues, primarily nausea and vomiting. In phase 3 trials for complicated skin/skin structure infections and intra-abdominal infections, nausea occurred in 26% of tigecycline patients vs. 13% on comparators, and vomiting in 18% vs. 9%. Diarrhea affected 13% vs. 10%, with most cases mild to moderate and highest early in treatment.[1][2]
How Often Do They Lead to Stopping Treatment?
GI effects prompt discontinuation in about 4-7% of patients on tigecycline, higher than comparators (2-3%). Nausea/vomiting drives most stops, though supportive care like antiemetics often manages them without interruption.[1][3]
Why Are GI Problems So Common with Tigecycline?
Its broad-spectrum action disrupts gut microbiota, similar to tetracyclines, leading to motility changes and toxin release. Unlike some antibiotics, tigecycline achieves high biliary concentrations, concentrating effects in the intestines. Risk rises with higher doses (e.g., 100mg loading then 50mg BID).[2][4]
What Do Real-World Studies Show?
Post-marketing data and meta-analyses confirm trial rates: a 2019 review of 20 trials found nausea in 23-30% and vomiting in 15-20%, with no major increase in severe diarrhea like C. difficile (1-2%). Observational studies in ICU settings report similar or slightly higher rates (up to 35% nausea) due to sicker patients.[3][5]
How Does Tigecycline Compare to Other Antibiotics?
Worse than comparators like vancomycin (nausea ~10%) or imipenem (vomiting ~8%), but similar to broad-spectrum options like ertapenem. It's notably higher than linezolid (nausea 5-7%). Prescribers often reserve it for multidrug-resistant infections where GI tolerability is a trade-off.[1][2]
Tips for Managing GI Issues
Start antiemetics (e.g., ondansetron) prophylactically, especially day 1. Slow infusion over 60 minutes reduces nausea. Food or splitting doses doesn't apply (IV only), but monitoring electrolytes helps as vomiting can cause imbalances.[4][6]
Sources
[1]: Tygacil Prescribing Information (Pfizer)
[2]: FDA Label Analysis
[3]: Meta-analysis, Clin Infect Dis 2019
[4]: IDSA Guidelines on Tigecycline
[5]: Real-world study, J Antimicrob Chemother 2020
[6]: UpToDate: Tigecycline Adverse Effects